title: Direct effects of GnRH agonists in human hormone-sensitive endometrial cells.
abstract: The antiproliferative effect of two GnRH agonists (leuprorelin acetate and triptorelin), alone or combined with tamoxifen (TAM) or medroxyprogesterone acetate (MPA), on human estrogen-sensitive endometrial cancer cells (Ishikawa) was investigated. Although ineffective when tested alone in all the culture conditions used, both analogues counteracted or even suppressed the estrogen-stimulated growth of Ishikawa cells. The antiestrogenic effect of TAM or MPA was not modified by their association with high doses of the GnRH analogues, but low concentrations of triptorelin combined with MPA 10(-7) M determined a reduction in cell numbers which was greater than that obtained with the progestin or the analogue alone. In addition, analogue treatment prevented the estrogen-induced decrease in the level of estrogen receptors. Our data provide evidence that GnRH agonists can directly inhibit estrogen-stimulated endometrial cancer cell growth and suggest that they may interfere with steroid-receptor machinery.
authors.affiliation: Istituto di Istologia ed Embriologia, Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Largo F. Vito, 1, 00168 Rome, Italy. ibiis@rm.unicatt.it
authors.forename: G
authors.initials: G
authors.lastname: Sica
authors.forename: G
authors.initials: G
authors.lastname: Schinzari
authors.forename: C
authors.initials: C
authors.lastname: Angelucci
authors.forename: G
authors.initials: G
authors.lastname: Lama
authors.forename: F
authors.initials: F
authors.lastname: Iacopino
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D004357:Drug Synergism; D016889:Endometrial Neoplasms / Q000378:metabolism / Q000473:pathology*; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D016729:Leuprolide / Q000494:pharmacology*; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D013629:Tamoxifen / Q000494:pharmacology*; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D004967:Estrogens; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D017329:Triptorelin Pamoate; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone; D017258:Medroxyprogesterone Acetate; D016729:Leuprolide